We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0IIM market cap is 4.31B. The company's latest EPS is USD -1.8401 and P/E is -1.18.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 148.36M | 227.55M | 78.45M | 75.48M | 116.33M |
| Operating Income | -93.1M | -121.4M | -226.73M | -179.5M | -155.56M |
| Net Income | -97.17M | -143.55M | -269.11M | -233.66M | -209.25M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 214.45M | 353.26M | 381.59M | 247.94M | 205.8M |
| Total Liabilities | 194.5M | 449.39M | 578.53M | 571.72M | 660.79M |
| Total Equity | 19.95M | -96.13M | -196.94M | -323.78M | -454.99M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -70.34M | -85.18M | -263.81M | -174.83M | -135.49M |
| Investing | 64.23M | 21.36M | -50.48M | 8.1M | 42.5M |
| Financing | 136.2M | 201.73M | 268.22M | 32.61M | 50.46M |
| Market Cap | 4.31B |
| Price to Earnings Ratio | -1.18 |
| Price to Sales Ratio | 2.12 |
| Price to Cash Ratio | 3 |
| Price to Book Ratio | -0.54 |
| Dividend Yield | - |
| Shares Outstanding | 113.72M |
| Average Volume (1 week) | 2.9k |
| Average Volume (1 Month) | 29.09k |
| 52 Week Change | 0.00% |
| 52 Week High | 37.89 |
| 52 Week Low | 37.89 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Esperion Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.esperion.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
